A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
Recruiting · NCT07127978
Conditions: Duchene Muscular Dystrophy
At a glance
- Research payments reported, 2025
- $109,934
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- ITF Therapeutics LLC
- Dates
- Started 2025-10-23; completion 2030-07-30
- Results posted
- Not yet
This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Itf Therapeutics LLC reported $109,934 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bridget Mcgowan, MD Child Neurology · Chicago, IL
- Stephen M. Chrzanowski, PHD Neurology · Worcester, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $66,465
- The University of Massachusets, Medical School $43,469
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.